Visual Function and Quality of Life Among Patients with Giant Cell (Temporal) Arteritis

Kupersmith, Mark J.; Speira, Robert; Langer, Regina; Richmond, Margorie; Peterson, Margaret G. E.; Speira, Harry; Mitnick, Hal J.; Paget, Stephen

doi:10.1097/00041327-200112000-00008

Cited by 34 publications

(29 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, patients with visual complications and those who reported visual problems in our specific questionnaire did not have lower scores in the specific SF36 QOL domains. These data are similar to Kupersmith et al's study, as their results did not show any significant QOL impairment in patients with visual loss at one year of GCA diagnosis [9]. However, patients who reported visual disturbances in our GCA specific questionnaire had a daily impairment score of 3 which corresponds to a Bmoderate^impairment and was the highest impairment score regarding all items.…”

Section: Resultssupporting

confidence: 89%

See 1 more Smart Citation

Quality of life of patients treated for giant cell arteritis: a case-control study

et al. 2017

View full text Add to dashboard Cite

The objective of the study was to assess the quality of life (QOL) of patients with giant cell arteritis (GCA), following high dose of corticosteroids (CS). Thirty patients with GCA who had stopped CS or who were under long-term low dose of CS were included and matched to 60 controls. QOL was measured by the SF-36 score and a specific questionnaire. GCA patients had no impairment of QOL compared to controls according to SF-36. Most of them (57%) estimated that their general condition was improved following treatment. Patients with GCA complications or CS therapy side effects had no significant impairment of their QOL compared with patients without complications or adverse effects. Only the patients who had gained weight had a lower score on the domain "Vitality" (VT; p = 0.013). Walking difficulties were the most frequent complaints. They were associated with impaired scores on the physical summary score (p = 0.0340) and on the "General Health" (GH; p = 0.005) and "Physical Functioning" (PF, p = 0.0298) domains. Falls among GCA patients were associated with altered scores on the domain VT (p = 0.0058) and on the mental summary score if they had fallen at least three times (p = 0.0460). GCA patients following high dose of CS or under long-term low doses of CS have no significant impairment of their QOL compared to controls. GCA complications, including visual impairment, do not seem to have any major impact on QOL.

show abstract

Section: Resultssupporting

confidence: 89%

“…So far, few studies have assessed QOL in patients with GCA. For Kupersmith et al, there was no correlation between BActivities of Daily Vision Scale^(ADVS) score, SF36 score, and visual impairment 1 year after GCA diagnosis [9]. Hellmann et al focused on the importance of several altered domains of QOL in GCA patients.…”

Section: Introductionmentioning

confidence: 99%

Quality of life of patients treated for giant cell arteritis: a case-control study

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Additional evidence included media degeneration or intima thickening 1. Visual acuity was expressed as a decimal (20/20 = 1.00; finger counting = 0.012; hand motion = 0.006; light perception = 0.001; no light perception = 0) 2. In order to compare steroids among patients, the doses in patients receiving a steroid other than hydrocortisone were converted according to the following dosing scheme: 1 mg dexamethasone = 30 mg hydrocortisone; 1 mg methylprednisolone = 5 mg hydrocortisone, 1 mg prednisone = 4 mg hydrocortisone.…”

Section: Methodsmentioning

confidence: 99%

Risk factors for early visual deterioration in temporal arteritis

Loddenkemper

Sharma

Katzan

et al. 2007

Journal of Neurology, Neurosurgery & Psychiatry

View full text Add to dashboard Cite

“…Therefore, patient preferences/perspectives should be incorporated into GCA assessment. In one study, the Medical Outcomes Study Short-Form 36 scores did not correlate with the presence of vision loss at baseline, systemic complications or side effects of steroid therapy13 while disease-specific instruments for GCA are currently unavailable. Moreover, we will probably need age-specific questionnaires to improve validity of outcomes measure in the elderly patients with GCA.…”

Section: Patient-reported Outcomesmentioning

confidence: 99%